Last updated on February 2019

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

Brief description of study

This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.

Clinical Study Identifier: NCT03398837

Find a site near you

Start Over

Hospital for Special Surgery

New York, NY United States
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »


Los Angeles, CA United States
  Connect »

Ninewells Hospital

Dundee, United Kingdom
  Connect »

Pacific Arthritis Care Center

Los Angeles, CA United States
  Connect »

Stanford University

Palo Alto, CA United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

University of Toledo

Toledo, OH United States
  Connect »

UTP Rheumatology Clinic

Houston, TX United States
  Connect »

Tulane University Medical Center

New Orleans, LA United States
  Connect »

Michigan Medicine

Ann Arbor, MI United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.